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Cytokine Thresholds in Gingival 
Crevicular Fluid with Potential 
Diagnosis of Chronic Periodontitis 
Differentiating by Smoking Status
N. Arias-Bujanda1, A. Regueira-Iglesias1, M. Alonso-Sampedro2, M. M. González-Peteiro1, 
A. Mira3, C. Balsa-Castro1 & I. Tomás1
The objective of the present study was to determine cytokine thresholds derived from predictive 
models for the diagnosis of chronic periodontitis, differentiating by smoking status. Seventy-five 
periodontally healthy controls and 75 subjects affected by chronic periodontitis were recruited. Sixteen 
mediators were measured in gingival crevicular fluid (GCF) using multiplexed bead immunoassays. 
The models were obtained using binary logistic regression, distinguishing between non-smokers and 
smokers. The area under the curve (AUC) and numerous classification measures were obtained. Model 
curves were constructed graphically and the cytokine thresholds calculated for the values of maximum 
accuracy (ACC). There were three cytokine-based models and three cytokine ratio-based models, which 
presented with a bias-corrected AUC > 0.91 and > 0.83, respectively. These models were (cytokine 
thresholds in pg/ml for the median ACC using bootstrapping for smokers and non-smokers): IL1alpha 
(46099 and 65644); IL1beta (4732 and 5827); IL17A (11.03 and 17.13); IL1alpha/IL2 (4210 and 7118); 
IL1beta/IL2 (260 and 628); and IL17A/IL2 (0.810 and 1.919). IL1alpha, IL1beta and IL17A, and their 
ratios with IL2, are excellent diagnostic biomarkers in GCF for distinguishing periodontitis patients from 
periodontally healthy individuals. Cytokine thresholds in GCF with diagnostic potential are defined, 
showing that smokers have lower threshold values than non-smokers.
Periodontitis is a public health problem, as it is highly prevalent and causes disability and social inequality1. 
In 2010, severe periodontitis was estimated to be the sixth most prevalent disease globally, affecting 743 mil-
lion people worldwide2. Periodontitis is currently being connected bidirectionally to the pathogenesis of various 
conditions and systemic diseases of high morbi-mortality such as diabetes, coronary heart disease, metabolic 
syndrome, chronic respiratory diseases, rheumatoid arthritis, cancer, obstetric complications and cognitive 
impairment3,4.
It is now widely accepted that, although the initiating factor is a polymicrobial dysbiosis5, the pathogenesis of 
periodontitis is driven by the development of a chronic inflammatory host immune response6,7. The nature and 
extent of this response are fundamental determinants of the susceptibility to and progression of periodontitis6,7.
Cytokines are soluble protein ‘messenger’ molecules produced by a variety of cells that transmit signals to 
other cells8. Cytokines play a crucial role in initiating and sustaining the inflammatory immune response by stim-
ulating the production of secondary mediators. These mediators, in turn, evoke a cascade of events that amplify 
the inflammatory response and induce the production of enzymes that are responsible for the degradation of 
connective tissue and osteoclastic bone resorption9.
Cytokines interact and function within a complex and dynamic network of interactions, rather than being 
dominated by the action of individual cytokines8. In fact, an imbalance between the pro-inflammatory and 
anti-inflammatory cytokines derived from Th1, Th2, Th17 and Treg lymphocyte subpopulations is suggested as 
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being responsible for periodontal breakdown through cellular and humoral hyper-immune responses10. However, 
the reductionist approach is predominant in vivo research, as very few authors have analysed the simultaneous 
presence of more than 10 cytokines11–13, or more than four cytokine ratios, in gingival crevicular fluid (GCF) from 
periodontal patients14,15. Accordingly, more evidence is required from multiple cytokine analyses to increase what 
is understood of this complex and dynamic network8.
On the other hand, the detection of biomarkers in GCF for predicting the early onset of periodontitis or eval-
uating the untreated or treated disease activity is a key challenge in periodontology16–18. There is, however, limited 
literature on the development and validation of predictive models based on GCF cytokine levels for the diagnosis 
or prognosis of periodontitis19,20.
Accordingly, the objectives of this cross-sectional study were:
 1. To compare the levels of 16 cytokines detected in GCF, as well as multiple cytokine ratios obtained from 
them, in periodontally healthy individuals and patients with chronic periodontitis.
 2. To determine the diagnostic value thresholds derived from cytokine-based and cytokine ratio-based mod-
els in non-smokers and smokers, selecting those models with a high discriminatory capacity to distinguish 
between periodontal patients and periodontally healthy controls.
 3. To validate cytokine-based and cytokine ratio-based models internally using bootstrapping techniques, 
describing their diagnostic thresholds, as well as apparent and corrected measures of discrimination and 
classification.
Materials and Methods
Selection of study groups. A sample of 150 eligible participants was recruited among 250 consecutive 
patients from the general population who were referred to the School of Medicine and Dentistry (Universidade de 
Santiago de Compostela, Spain) for an evaluation of their oral health status between 2013 and 2015. This sample 
consisted of all the cases (patients with the target condition, that is, 75 subjects affected by moderate to severe 
generalised chronic periodontitis -perio group-) and a random sample of the noncases (75 periodontally healthy 
controls -control group-). Patients were selected if they fulfilled the inclusion criteria, which are detailed in the 
footnote of Table 1.
One previously calibrated, experienced dentist performed all the periodontal examinations. The probing 
pocket depth (PPD) and clinical attachment level (CAL) were recorded on all teeth at six sites per tooth using 
a PCP-UNC 15 probe. Bleeding on probing (BOP) and bacterial plaque level (BPL) data were recorded for the 
full mouth on a binary scale (presence/absence) on six sites per tooth. Standardised radiographs of all teeth were 
obtained to assess the alveolar bone status.
The presence of periodontal health or moderate to severe generalised chronic periodontitis was established 
according to the clinical/radiographic information, applying previously published criteria21,22. Smoking histories 
were obtained using a questionnaire, with information collected on smoking status (never, past or current, the 
number of months of smoking and the number of cigarettes/day). All the answers were reviewed with the subject 
by a member of the study team.
This study was conducted according to the principles outlined in the Declaration of Helsinki (as revised in 
2000) on experimentation involving human beings23. The TRIPOD guidelines were considered for further pre-
dictive analysis24.
Gingival crevicular fluid sampling. The GCF collection took place one week after the initial examination, 
and the samples were obtained at the same time of day (in the afternoon, approximately 5–7 h after toothbrush-
ing). A paper strip (Periopaper, Amityville, NY, USA) was inserted into the gingival sulcus or periodontal pocket 
for 30 sec, using a GCF collection protocol previously described25. GCF samples from the controls and periodon-
tal patients were collected and pooled from 20 non-adjacent proximal sites. In the first case, samples were taken 
from subgingival sites from teeth in quadrants 1 and 3, and in the second case from sites from the most in-depth 
PPD in each quadrant.
Strips from each subject were inserted into labelled tubes with 300 ml of 0.01 M PBS (pH = 7.2) and a protease 
inhibitor (Complete Mini, protease inhibitor cocktail tablets, Roche Applied Science, Indianapolis, IN, USA). 
To ensure sample collection, the GCF volume was determined based on measurements of weighing the tubes 
and strips before and after sampling using a very sensitive scale26 (readability of 0.01 mg; Explorer Semi Micro 
Ex125M, OHAUS, Greifensee, Switzerland). All the samples collected had volumes of GCF ≥ 10 µl. After obtain-
ing the supernatant, the GCF samples were frozen at −80 °C until further biochemical analysis.
Quantification of cytokines in gingival crevicular fluid using multiplexed bead immuno-
assays. GCF cytokine levels were determined using the human cytokine 16-plex Procarta immunoassay 
(Affymetrix, Inc., Santa Clara, CA, USA). Sixteen mediators were measured: granulocyte-macrophage colony 
stimulating factor – GMCSF; IFNgamma; IL1alpha; IL1beta; IL2; IL3; IL4; IL5; IL6; IL10; IL12p40; IL12p70; IL13; 
IL17A; IL17F; and TNFalpha.
A single investigator blinded to the clinical data performed the experimental analyses of the GCF cytokine 
quantification. The assays were performed in 96-well filter plates following the manufacturer’s instructions and 
applying an analysis protocol described previously25. The GCF samples were quantified using the Luminex 100™ 
instrument (Luminex Corporation, Austin, Texas, USA) and all of them were run in duplicate. The concentra-
tions of the unknown samples were estimated from the standard curve using a 5PL algorithm and the Luminex IS 
2.3 and xPONENT 3.1 software packages (Luminex Software, Inc.). Values were expressed as pg/ml adjusting for 
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the dilution factor. Samples below the detection limit (DL) of the assay were recorded as DL/227, while those above 
the upper limit of quantification of the standard curves were assigned the highest value of the curve.
Statistical analysis. The statistical analyses were performed using the R software (version 3.4.3)28. It is avail-
able as Free Software under the terms of the Free Software Foundation’s GNU General Public License in source 
code form. After applying the Shapiro-Wilks test and verifying the non-normal distribution of almost all the 
clinical variables, the Mann-Whitney U test was used to compare the quantitative variables between the perio and 
control groups. The Fisher’s exact test was used to assess the association of the qualitative variables between both 
study groups. The significance level applied was a p-value < 0.05.
Comparison of GCF cytokine levels and cytokine ratio values in periodontally healthy individ-
uals and patients with chronic periodontitis. After verifying the non-normal distribution of variables 
using the Shapiro-Wilks test, the Mann-Whitney U test was used to compare the cytokine levels and cytokine 
ratios in the control and perio groups. The significance levels applied were adjusted by the Benjamini-Hochberg 
correction29, with p-values ≤ 1 × 10−3 and <1 × 10−5, respectively. A total of 66 cytokine ratios were evaluated, 
taking into account exclusively those cytokines that showed significant levels in the periodontal patients com-
pared to the controls (Fig. 1).
Predictive modelling of chronic periodontitis based on cytokine levels and cytokine ratios: 
model selection; discrimination and classification measures; determination of diagnostic 
thresholds; and internal validation. To obtain specific diagnostic thresholds differentiating by smok-
ing status, we decided to develop different models for non-smokers and smokers (n = 93 and 54, respectively). 







(n = 73) P Value





No. of teeth 26.72 (3.25) 25.55 (4.00) NS
Full mouth
BPL (%) 26.41 (18.66) 53.08 (26.77) <0.001
BOP (%) 15.05 (6.61) 51.12 (20.07) <0.001
PPD (mm) 2.11 (0.27) 3.49 (0.65) <0.001
CAL (mm) 2.36 (0.46) 4.25 (1.12) <0.001
Sampled sites
BOP (%) 10.11 (10.24) 66.97 (23.93) <0.001
PPD (mm) 2.23 (0.22) 5.65 (0.89) <0.001





Cigarettes/day (no.) 8.08 (4.44) 15.20 (7.94) 0.001
Months of smoking (no.) 236.38 (155.91) 320.78 (109.03) NS
Table 1. Age, gender, smoking habit and clinical characteristics associated with the periodontal status in the 
control and perio groups. Values are means (standard deviations) and number of subjects. BPL = bacterial 
plaque level; BOP = bleeding on probing; PPD = probing pocket depth; CAL = clinical attachment level; 
NS = not significant. In this series, the inclusion criteria applied were: 1) age 30 to 75; 2) no medical history of 
diabetes mellitus or hepatic or renal disease, or other serious medical conditions or transmittable diseases; 3) 
no history of alcohol or drug abuse; 4) no pregnancy or breastfeeding; 5) no intake of systemic antimicrobials 
during the previous six months; 6) no intake of anti-inflammatory medication in the previous four months; 
7) no routine use of oral antiseptics; 8) no presence of implants or orthodontic appliances; 9) no previous 
periodontal treatment; 10) smokers who had stopped smoking less than five years before the sampling; and 
11) the presence of at least 18 natural teeth. aOf the 150 patients who fulfilled the inclusion criteria and had 
an adequate periodontal diagnosis, three were excluded for unexpected events. The control group included 
periodontally healthy individuals with BOP < 25%, no sites with a PPD ≥ 4 mm and no radiographic evidence 
of alveolar bone loss. Considering previously established criteria21,22, patients in the perio group were diagnosed 
with moderate to severe generalised chronic periodontitis. bA patient was defined as a smoker if he/she was 
currently smoking and had been a smoker for at least eight years) and as a non-smoker if he/she had never 
smoked or had stopped smoking more than five years before the sampling.
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The statistical criterion applied for the model selection was the ability of each cytokine- or cytokine ratio-based 
model to determine the presence of chronic periodontitis using the value of the area under the curve (AUC)30. 
The AUC values and their corresponding 95% confidence intervals (CIs) obtained by bootstrapping were calcu-
lated using the pROC package (version 1.10.0)31. Only those models that presented an apparent AUC ≥ 0.85 in 
both types of model for smokers and non-smokers were selected32.
The best cut-off value or optimal classification threshold for each model was defined as that which provides 
the maximum percentage of correct predictions (accuracy, ACC), and was calculated using the PresenceAbsence 
package (version 1.1.9)33. By setting this optimal value, various classification measures such as the ACC, sensitiv-
ity, specificity, positive predictive value (PPV), and negative predictive value (NPV), as well as their correspond-
ing 95% CIs acquired by bootstrapping, were obtained using the pROC package31. The respective cytokine levels 
or cytokine ratios were calculated for all the periodontitis probability values of each model, and the model curves 
were constructed graphically using the ggplot package (version 2.2.1)34.
Regarding internal validation, bootstrapping was used to test for possible overfitting by determining the opti-
mism values on the discrimination and classification measures. The bootstrap analysis was replicated on 10,000 
random samples of the same sample size, drawn with replacements from the original sample35,36. Bias-corrected 
(bc) AUC and all other classification measures (bc-sensitivity, bc-specificity, bc-PPV, bc-NPV) were calculated as 
their corresponding apparent measures derived from the entire original sample minus optimism35,36. This tech-
nique was also used to define the cytokine thresholds for the median ACC values derived from 10,000 samples 
from each model selected, as well as the thresholds for the 90% CIs of the ACC values (Fig. 1).
Ethics approval and consent to participate. The study’s protocol was approved by the Clinical Research 
Ethics Committee of Galicia (number 2015/006). Patients who agreed to participate in the research provided 
written informed consent.
Results
The mean age of the study group was 48.37 ± 11.55 years; 62 individuals were male and 85 female. The perio 
group had significantly higher BPL, BOP, PPD and CAL values than the control group at both the full mouth and 
sampling site levels (p < 0.001; Table 1). The number of smokers was significantly higher in the perio group than 
in the control group (41 and 13 patients, respectively, p < 0.001; Table 1).
Comparison of GCF cytokine levels and cytokine ratio values in periodontally healthy individ-
uals and patients with chronic periodontitis. All the pro-inflammatory cytokines analysed (GMCSF, 
IL1alpha, IL1beta, IL6, IL12p40, IL17A, IL17F and TNFalpha), as well as four cytokines with anti-inflammatory 
Figure 1. Flow chart of the statistical analysis: binary logistic regression and diagnostic thresholds. AUC: 
area under the curve; ACC: accuracy; Sens: sensitivity; Spec: specificity; PPV: positive predictive value; NPV: 
negative predictive value; CIs: confidence intervals.
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effects (IFNgamma, IL2, IL3 and IL4), had significantly higher levels in the perio group than in the control 
group (adjusted p-value ≤ 1 × 10−3). Nineteen cytokine ratios showed significant differences between the con-
trol and perio groups (adjusted p-value < 1 × 10−5). Of these ratios, nine were based on the combination of two 
pro-inflammatory cytokines, which were: IL1alpha combined with GMCSF, IL12p40 and TNFalpha; and IL1beta 
combined with GMCSF, IL12p40, IL17F or TNFalpha, GMCSF/IL17A and IL17A/IL17F. The remaining 10 ratios 
were based on the combination of one pro-inflammatory cytokine and one cytokine with anti-inflammatory 
effects. These were: IL1alpha/IL2; IL1alpha/IL3; IL1alpha/IFNgamma; ILbeta/IL2; ILbeta/IL3; ILbeta/IL4; ILbeta/
IFNgamma; IL17A/IL2; IL17A/IL3; and IL17A/IFNgamma. All these cytokine ratios, except for GMCSF/IL17A, 
had significantly higher values in the perio group than in the control group (Table 2).
Predictive modelling of chronic periodontitis based on GCF cytokine levels and cytokine 
ratios: model selection; discrimination and classification measures; determination of diagnos-
tic thresholds; and internal validation. There were three cytokine-based models and three cytokine 
ratio-based models, which had an apparent AUC ≥ 0.85 for both non-smokers and smokers. These models were 
IL1alpha, IL1beta, IL17A, IL1alpha/IL2, IL1beta/IL2 and IL17A/IL2.
Apparent and bc-percentages of discrimination and classification of the six predictive models are described 
in Table 3. The cytokine-based models had AUC and bc-AUC values ≥ 0.940 and ≥ 0.912, respectively, and the 




Control group Perio group
Adjusted 
p-value
GMCSF 150.24 (129.67) 247.24 (255.55) 7.29E-05
IL1alpha 30405.78 (20713.06) 148825.83 (221175.10) 2.64E-21
IL1beta 2881.75 (1958.43) 17947.50 (17308.08) 5.59E-21
IL6 166.71 (163.90) 313.45 (461.34) 3.77E-06
IL12p40 7.34 (5.65) 17.30 (11.06) 7.10E-12
IL17A 7.53 (9.38) 28.45 (25.83) 9.70E-19
IL17F 3.40 (7.01) 9.62 (15.47) 7.75E-09
TNFalpha 6.46 (13.49) 22.75 (15.95) 2.50E-04
IFNgamma 4.71 (3.85) 9.55 (9.60) 3.42E-07
IL2 9.96 (8.74) 14.96 (8.08) 0.001
IL3 54.26 (37.15) 99.60 (89.75) 1.23E-05
IL4 5.96 (21.42) 12.37 (47.02) 2.50E-04
CGF Cytokine Ratio
GMCSF/IL17A 26.57 (25.02) 7.76 (14.82) 2.80E-08
IL1alpha/GMCSF 218.44 (198.78) 631.24 (1434.02) 1.03E-11
IL1alpha/IL12p40 4531.12 (3831.16) 6849.23 (17879.96) 2.78E-06
IL1alpha/TNFalpha 4524.95 (5930.96) 8427.24 (22799.21) 7.71E-06
IL1beta/GMCSF 19.52 (24.42) 67.75 (97.45) 1.18E-12
IL1beta/IL12p40 402.43 (516.02) 844.61 (1378.24) 2.83E-08
IL1beta/IL17F 662.10 (964.59) 1446.37 (3287.34) 1.62E-06
IL1beta/TNFalpha 468.80 (583.89) 854.64 (1669.85) 2.49E-07
IL17A/IL17F 0.88 (2.46) 2.31 (4.79) 1.88E-06
IL1alpha/IL2 3279.43 (3601.17) 8890.94 (17774.01) 1.93E-14
IL1alpha/IL3 630.99 (759.95) 2262.85 (5590.86) 1.42E-10
IL1alpha/IFNgamma 7728.27 (4744.27) 18426.38 (52652.97) 3.05E-12
IL1beta/IL2 260.08 (210.23) 1249.52 (1480.05) 4.16E-14
IL1beta/IL3 66.56 (87.48) 206.71 (469.16) 8.04E-11
IL1beta/IL4 536.43 (702.25) 1530.57 (2756.95) 7.25E-06
IL1beta/IFNgamma 805.90 (387.53) 2084.77 (5776.57) 5.54E-13
IL17A/IL2 0.64 (0.58) 1.96 (1.41) 5.54E-13
IL17A/IL3 0.13 (0.12) 0.34 (0.32) 4.80E-11
IL17A/IFNgamma 1.81 (1.03) 3.14 (2.03) 4.20E-12
Table 2. Concentrations of cytokines and cytokine ratios that showed significant differences (adjusted p-
values ≤ 1 × 10−3 and <1 × 10−5, respectively) between the control and perio groups. IQR, interquartile range; 
CGF, crevicular gingival fluid. Concentration range for each biomarker analysed: GMCSF, 0.53–55,050 pg/ml; 
IFNgamma, 0.02–6,650 pg/ml; IL1alpha, 0.34–28,800 pg/ml; IL1beta, 0.09–23,150 pg/ml; IL2, 0.04–13,700 pg/
ml; IL3, 0.19–26,500 pg/ml; IL4, 0.10–29,250 pg/ml; IL5, 0.04–17,800 pg/ml; IL6, 0.10–27,200 pg/ml; IL10, 
0.04–10,050 pg/ml; IL12p40, 0.14–27,350 pg/ml; IL12p70, 0.26–18,050 pg/ml; IL13, 0.34–23,700 pg/ml; IL17A, 
0.36–30,900 pg/ml; IL17F, 0.25–34,700 pg/ml; TNFalpha, 0.21–16,800 pg/ml.
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cytokine-based models was 86.8–94.1% and that of the cytokine ratio-based models was 72.9–88.7%, with IL17A 
and IL17A/IL2 being the biomarkers with the lowest bc-ACC values in both smokers and non-smokers. The 95% 
CIs of the model coefficients and those of the performance measures are detailed in Supplementary Dataset 1.
The periodontitis probability range for the median ACC values varied between 23 and 51%. The cytokine 
thresholds in pg/ml for the median ACC values (and those for the 95% CIs of the ACC values) for smokers 
and non-smokers were, respectively: IL1alpha model: 46099 (37495–64161) and 65644 (51310–76700); IL1beta 
model: 4732 (3705–6459) and 5827 (4721–7532); IL17A model: 11.03 (7.28–15.22) and 17.13 (13.10–22.53); 
IL1alpha/IL2 model: 4210 (3164–5648) and 7118 (4798–10166); IL1beta/IL2 model: 260 (63–487) and 628 (348–
897); and IL17A/IL2 model: 0.810 (0.707–1.132) and 1.919 (1.073–3.489). The range of cytokine thresholds rep-
resented around 9–13% of the cytokine or ratio measurement range, except for IL17/IL2 for non-smokers (30%). 
Compared to the non-smokers, the smokers had lower diagnostic thresholds on all the predictive models for both 
apparent ACC values and ACC values obtained by bootstrapping (Figs 2–4).
Discussion
High cytokine concentrations and cytokine ratios in the gingival crevicular fluid of patients 
with chronic periodontitis. As mentioned in the Introduction, there has been a failure to study a broader 
spectrum of cytokines that may directly influence the local inflammatory response in different types of perio-
dontitis37. The present series is the first comparative analysis of more than 50 cytokine ratios derived from the 
simultaneous quantification of 16 cytokines with different roles in the pathophysiology of chronic periodontitis7,8.
It should be noted that a particularly strict corrected significance value was applied (adjusted p-value < 1 × 10−5) 
in order to select the cytokine ratios with the most significant impact on chronic periodontitis. This statistical 
decision conditioned the ratios considered to be non-significant and significant. As a consequence, comparisons 
with the contributions of other authors must be interpreted with caution.
Although very few authors have investigated the ratios between pro-inflammatory cytokines in periodon-
titis38–40, up to eight pro-inflammatory cytokine ratios showed significant differences in periodontal patients. 
Although we detected significantly elevated levels of all the pro-inflammatory cytokines analysed, IL1alpha and 
IL1beta were the most important biomarkers in terms of increased concentration associated with the disease. 
This resulted that the ratios based on IL1alpha combined with GMCSF, IL12p40 or TNFalpha, and IL1beta com-
bined with GMCSF, IL12p40, IL17F or TNFalpha, showed significantly higher values in the periodontal patients. 
Coinciding with the results reported by Azman et al.41, we also obtained a significantly elevated IL17A/IL17F 
ratio in the patients with chronic periodontitis. Interestingly, in this series, and unlike the other pro-inflammatory 
cytokine ratios, the GMCSF/IL17A ratio had significantly lower values in the periodontal patients, representing 
the first evidence of the impact of this ratio in the pathogenesis of periodontitis.
Most previous studies have focused on the analysis of ratios between pro-inflammatory and anti-inflammatory 
























































































































































Table 3. Apparent and bias-corrected measures of discrimination and classification of the models based on 
cytokines and citokine ratios for both smokers and non-smokers. In each cell, the first value is referred to 
the apparent performance measures and the second to the corrected performance measures by the level of 
optimism, calculated using a bootstrap procedure. The 95% CIs of the different performances measures are 
detailed in Supplementary Dataset 1.
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evaluated14,38,42–45. In the present series, up to nine ratios based on the combination of one pro-inflammatory 
cytokine (IL1alpha, ILbeta or IL17A) and one cytokine with anti-inflammatory effects (IFNgamma, IL2, IL3 or 
IL4) showed significantly higher values in the periodontal patients. These results were due to the higher mean 
concentrations of pro-inflammatory cytokines compared to the levels presented by anti-inflammatory cytokines. 
In contrast to the findings of Stadler et al.46, these mediators also showed a significant mean increase associated 
with chronic periodontitis. On the other hand, applying multivariate predictive modelling techniques, we have 
previously demonstrated that the extent of the periodontitis-associated imbalance between IL1alpha, ILbeta or 
IL17A (acting as enhancers) and IFNgamma, IL2, IL3 or IL4 (acting as protectors) was associated with a particu-
lar probability of having chronic periodontitis25.
We have not found any articles that would enable us to compare our findings on ratios between IL1alpha 
and different anti-inflammatory cytokines. Regarding the ratios between ILbeta and other anti-inflammatory 
cytokines, some authors have observed that: the ILbeta/IL10 ratio was increased in the GCF or gingival tissue 
of patients with aggressive periodontitis or chronic periodontitis14,42,43; this ratio was significantly reduced after 
periodontal therapy43. However, after studying these papers in detail, these results can be attributed mainly to 
significantly higher mean levels of IL1beta, while the levels of IL10 showed non-significant individual variations. 
These results obtained in vivo call into question the importance of this ratio in the pathogenesis of periodontitis. 
Likewise, in the present study, no significant differences in IL10 levels between the controls and periodontal 
Figure 2. Model curves based on IL1alpha and IL1alpha/IL2, defining the diagnostic thresholds for apparent 
and median ACC values, as well as those thresholds for the 90% CIs of the ACC values.
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patients were detected, and so the IL1beta/IL10 ratio was not evaluated. However, it should be noted that IL10 
acquired a greater protagonism as an anti-inflammatory cytokine within a two-biomarker predictive model, as 
this increased the capacity of IL1beta to discriminate the chronic periodontitis state25. In contrast, in the present 
series, we observed that other ratios, such as IL1beta/IFNgamma, ILbeta/IL2, ILbeta/IL3 and ILbeta/IL4, may 
play an essential role in quantitative terms in chronic periodontitis. Several studies have revealed that the IL11/
IL17 ratio was reduced in patients with chronic and aggressive periodontitis44,45,47, although other authors have 
described conflicting findings38. In the present study, other ratios such as IL17A/IFNgamma, IL17A/IL2, IL17A/
IL3 and IL17A/IL4 had significantly higher values in the periodontal patients, reflecting their impact on chronic 
periodontitis.
Consequently, this study is the first time that evidence is provided on a high number of ratios between 
pro-inflammatory cytokines or pro-inflammatory and anti-inflammatory cytokines that, due to their perfor-
mance in GCF samples, could be biomarkers associated with chronic periodontitis. Future research is required to 
clarify the relevance of these ratios in the chronic periodontitis pathogenesis.
High predictive ability of GCF cytokine levels and cytokine ratios for the diagnosis of chronic 
periodontitis. Due to the characteristics of cytokine networks48, whether cytokines in GCF may show an 
acceptable ability to discriminate chronic periodontitis from periodontal health is questioned. However, this 
Figure 3. Model curves based on IL1beta and IL1beta/IL2, defining the diagnostic thresholds for apparent and 
median ACC values, as well as those thresholds for the 90% CIs of the ACC values.
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affirmation is supported by little evidence, as there are very few studies that have evaluated the predictive prop-
erties of cytokines in chronic and aggressive periodontitis using an appropriate experimental design19,20. The 
current series reveals the first results on the predictive ability of cytokines and cytokine ratios for the diagnosis 
of chronic periodontitis, differentiating between smokers and non-smokers. Moreover, internal validation was 
carried out for the first time on the predictive parameters obtained, as recommended in the TRIPOD guidelines24.
In this study, in relation to individual cytokines, and corroborating observations published previously by 
our research group25, there were three models consisting of IL1alpha, IL1beta and IL17A, which presented a 
bc-AUC > 0.90 for both smokers and non-smokers. According to experts in the field32, these high AUC val-
ues indicate that these pro-inflammatory cytokines have a great capacity to discriminate the disease condition. 
Consequently, these pro-inflammatory cytokines were associated with elevated bc-ACC percentages: 90.7% (for 
IL1beta), 90.3% (for IL17A) and 89.4% (for IL1alpha) in smokers; and 94.1%, 86.8% and 92.4%, respectively, in 
non-smokers. Findings on IL1’s high predictive ability are consistent with those previously described by Baeza et al.20, 
while IL17’s findings represent the first evidence of a strong diagnostic capability. In our opinion, our results on 
the high predictive potential of these cytokines are comparable to those found for other well-known biomarkers, 
such as different metalloproteinases20.
We evaluated the cytokine ratios using predictive modelling techniques, with the aim being to identify a set of 
biomarkers that guarantee a high diagnostic predictability16. In this sense, we obtained three ratio-based models 
Figure 4. Model curves based on IL17A and IL17A/IL2, defining the diagnostic thresholds for apparent and 
median ACC values, as well as those thresholds for 90% CIs of the ACC values.
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consisting of IL1alpha/IL2, IL1beta/IL2 and IL17A/IL2, which presented a bc-AUC > 0.80 for both smokers and 
non-smokers. These bc-AUC values, although lower than those detected in individual cytokines, were also very 
high, revealing that these cytokine ratios were associated with an excellent ability to discriminate periodontitis 
patients32.
For the first time in the literature, we have defined specific thresholds with diagnostic potential for each smok-
ing status. These were derived from cytokine- and cytokine ratio-based predictive models, and their validity was 
verified given that the apparent ACC and median ACC values derived from the bootstrap approaches were simi-
lar. On the other hand, the range of thresholds obtained by bootstrapping represented only around 9–13% of the 
measurement range of the biomarkers (except for the IL17A/IL2 ratio in non-smokers). Accordingly, the upper 
and lower thresholds of these ranges would ensure optimal diagnostic classification.
In line with the trend of attempting to discover biomarkers to improve the clinical diagnosis of periodontal 
diseases16–18, the determination of these specific thresholds could represent a first step in the design and construc-
tion of chronic periodontitis diagnostic kits for use in clinical practice.
As smoking is a well-established traditional risk factor for chronic periodontitis49,50, we demonstrated previ-
ously from a predictive perspective that smoking status increases the probability of having chronic periodontitis 
by 15–20%25. Interestingly, in the present series, smokers had lower diagnostic thresholds than non-smokers. At a 
biochemical level, this justifies what is observed at a clinical level, i.e. the presence of a less intense inflammatory 
reaction in smoking-associated periodontitis, indicating that smoking may have an immunosuppressant effect49. 
Secondly, it reveals the convenience of designing biomarker studies for predicting periodontal diseases differen-
tiating by smoking status, especially if the diagnostic thresholds are to be defined.
Our research has some limitations. Although we are in a scenario of small data, the sample size used allowed 
certain metrics of model performance were estimated with an acceptable precision24; in addition, a strict model 
selection criterion (apparent AUC value ≥ 0.85) was applied for both non-smokers and smokers. An internal 
validation process was carried out using bootstrap techniques, with the aim being to counteract the prediction 
that the study’s accuracy is only measured in the samples that generated the model equations24. Although the 
results derived from the internal validation were quite optimal, the predictive parameters and diagnostic thresh-
olds obtained from our models should be evaluated in an external cohort of patients (including using calibration 
analyses) to verify whether our findings are applicable universally.
In conclusion, a high number of previously undescribed GCF cytokine ratios are elevated in patients with 
chronic periodontitis, evidencing disease-associated imbalances between cytokines with pro-inflammatory 
and anti-inflammatory effects. IL1alpha, IL1beta and IL17A, and their ratios with IL2, are excellent diagnostic 
biomarkers in GCF for distinguishing periodontitis patients from periodontally healthy individuals. Cytokine 
thresholds in GCF with diagnostic potential are defined, showing that smokers have lower threshold values than 
non-smokers.
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